Drug Trial Radar · NCT05758896
Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI
Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
218
Actual
Start
Dec 27, 2023
Primary completion
Jul 22, 2026
Study completion Jul 22, 2026
Sponsor
- Lead sponsor
- Aptabio Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 2 study is to assess the safety and efficacy of APX-115 active doses in Contrast Induced Acute Kidney Disease compared to placebo following multiple oral dosing in patients with undergoing percutaneous coronary intervention. It is anticipated that approximately 230 patients will be randomized into the study in a 1:1 ratio to 400 mg APX-115 (Isuzinaxib hydrochloride) or placebo arm.
Conditions
- Contrast Induced Acute Kidney Injury
Interventions
Isuzinaxib (APX-115)Drug
Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
PlaceboDrug
Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety endpoints: adverse eventTime frame: Day -2 to day 84
- Safety endpoints: vital signTime frame: Day 0 to day 84
- Safety endpoints: physical examTime frame: Day 0 to day 84
- Safety endpoints: ECGTime frame: Day 0 to day 84
- Safety endpoints: labsTime frame: Day 0 to day 84
Locations
14 sites in 2 countries. Site status is shown where the registry gives one.
Baylor Scott & White Research Institute
Dallas, Texas
Kangwon National University Hospital
Chuncheon, South Korea
Keimyung University Dongsan Hospital
Daegu, South Korea
Chungnam National University Hospital
Daejeon, South Korea
Inje University Ilsan Paik Hospital
Goyang, South Korea
Chonnam National University Hospital
Gwangju, South Korea
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Kangbuk Samsung Hospital
Seoul, South Korea
Korea University Anam Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
The Catholic University of Korea Seoul St. Mary's Hospital
Seoul, South Korea
The Catholic University of Korea St. Vincent's Hospital
Suwon, South Korea
Ulsan University Hospital
Ulsan, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.